8 am – 8:45 am
General session 5
Coordinator:
Discussants:
Dr. Jahanzeb is the Co-Founder and President of OncAdvisor (a concierge oncology second opinion company) and co-founded PrecisCa (a virtual multidisciplinary and multi-institutional expert tumor panel for point-of-care second opinions). His most recent practice sites were Florida Cancer Specialists and Florida Precision Oncology. He was formerly a Professor of Clinical Medicine, Hematology/Oncology at University of Miami’s Miller School of Medicine, where he also served as the Associate Director of Community Outreach and Medical Director of the Deerfield Campus for the Sylvester Comprehensive Cancer Center for about nine years. He received his oncology training at Washington University/Barnes-Jewish Hospital in St. Louis, MO, where he subsequently served on Faculty. He has practiced and led clinical research in lung and breast cancer medical oncology for about 30 years.
National leader of the Oncoclínicas Group Survivorship program. PhD in Sciences from the Faculty of Medicine of the University of São Paulo - FMUSP. Member of the SBOC Breast Tumor Committee 2022-2024. Medical Coordinator of the Clinical Research Center of the Oncoclínicas Group - Bahia. Leader of breast oncology at the Oncoclínicas Group - Bahia.
8 am – 8:10 am
Dose-dense versus 3-weekly AC during Neoadjuvant Chemoimmunotherapy for Early-Stage Triple-Negative Breast Cancer: GBECAM 0123 – The Neo-Real Study
8:10 am – 8:20 am
Distinct expression of miRNAs and its association with survival in TNBC and non-TNBC breast tumors subtypes from a cohort of patients from South of Brazil
8:20 am – 8:30 am
Enrichment of intestinal Bifidobacterium genus is associated with residual disease among patients with early-stage HER2+ breast cancer (BC) following neoadjuvant chemotherapy (NACT)
8:30 am – 8:40 am
Discussion
8:45 am – 9:05 am
Mini Conference: When should a patient with metastatic breast cancer undergo surgery? The experience of japanese clinical oncology group
Chairwoman:
Gynecology and Obstetrics at the Santa Casa de Misericórdia Hospital in Goiânia. Fellowship in Gynecological Oncology at Hospital Araujo Jorge. Postgraduate in Palliative Care PUC / ACCG. Sub-investigator at the Gynecology and Breast Research Center at HAJ. Oncological Gynecologist on the Gynecology and Breast team at Hospital Araujo Jorge in Goiânia - GO and Unicca in Anápolis - GO.
Speaker:
Dr. Tadahiko Shien MD, Ph.D. (Ph.D.-surgical medicine) is a director of the Breast and Endocrine Surgery Department at Okayama University Hospital and the JCOG Breast Cancer Study Group chair. He is a surgical oncologist researching the treatment strategy for de-novo stage IV breast cancer (PI of JCOG1017 study) and Oligometastasis. His clinical and research interests primarily focus on breast surgical oncology, tumor biology, clinical trials, and translational research. He is a member of the American Society of Clinical Oncology (ASCO), Japan Surgical Society (JSS), Japan Society of Clinical Oncology (JSCO), Japan Breast Cancer Society (JBCS), Japan Society of Medical Oncology (JSMO), International Society of Surgery (ISS), Japan Oncoplastic Breast Surgery Society (JOBSS), Japan Association of Endocrine Surgery (JAES), and Breast Surgery International (BSI). His board-certified specialties are JSS, JSCO, and JAES, and the Board of JBCS and JAES. He is an associate editor of BMC Women’s Health, Frontier in Oncology, and Oncology letters.
9:10 am – 9:50 am
Diamond Satellite Symposium – ASTRAZENECA – HER2 treat: low HER2 expression as a target in breast cancer
Speaker:
Clinical Oncologist, Head of Oncology Research and National Breast Cancer Leader - DASA Oncologia. Postdoctoral fellow in the Department of Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School.
9:50 am – 10:20 am
Coffee Break
10:20 am – 10:50 am
Mini conference: The philosophical view on breast cancer treatment: from the other side of the table
Chairman:
Speaker:
Degree in Philosophy, qualification in pedagogy. Master's and PhD in Philosophy and PhD student in Religious Sciences. Prof. PUC-Goiás.
10:55 am – 11:35 am
Table: How to de-escalate treatment in EC I, luminal tumors. Where do I bet my chips?
Coordinator:
Speakers:
15’ De-escalate axilla and maintain whole breast irradiation
Doctor at the Oncoclínicas Group and Hospital Israelita Albert Einstein. Director of the Brazilian School of Mastology.
Speakers:
15’ De-escalate radiotherapy (partial) and maintain BLS
Professor of Surgery. Division of Surgical Oncology. Director, Breast Surgery Oncology Fellowship.
11:35 am – 11:55 am
Mini conference: CDK4/6 inhibitors after patent expirations: how affordability can change the landscape of HR+/HER2- metastatic breast cancer
Chairman:
Speaker:
11:55 am – 12:35 pm
Lecture: The best of breast cancer in the last 12 months (ASCO 2023, SABS 2023 and BBCS 2024)
Chairman:
Clinical oncologist at the Ihg Oncology Center in Goiânia and the Instituto Onco Hematológico de Anápolis.
Speaker 1:
20’ Systemic
Dr. Jahanzeb is the Co-Founder and President of OncAdvisor (a concierge oncology second opinion company) and co-founded PrecisCa (a virtual multidisciplinary and multi-institutional expert tumor panel for point-of-care second opinions). His most recent practice sites were Florida Cancer Specialists and Florida Precision Oncology. He was formerly a Professor of Clinical Medicine, Hematology/Oncology at University of Miami’s Miller School of Medicine, where he also served as the Associate Director of Community Outreach and Medical Director of the Deerfield Campus for the Sylvester Comprehensive Cancer Center for about nine years. He received his oncology training at Washington University/Barnes-Jewish Hospital in St. Louis, MO, where he subsequently served on Faculty. He has practiced and led clinical research in lung and breast cancer medical oncology for about 30 years.
Speaker 2:
20’ Loco regional
Professor of Surgery. Division of Surgical Oncology. Director, Breast Surgery Oncology Fellowship.
12:35 pm – 1pm
Awarding and closing remarks
